Revive Therapeutics partners with India-based specialty pharma Supriya Lifescience to advance Bucillamine to treat coronavirus

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) says it has moved its global commercialization plans for Bucillamine to treat coronavirus (COVID-19) a step further by partnering with India-based specialty pharma Supriya Lifescience Ltd.  The company has struck a memorandum of understanding (MoU) with Supriya for the manufacturing, clinical registration and commercialization of the drug through Emergency Use Authorization (EUA) in India, a country hit hard by the virus.  READ: Revive Therapeutics inks feasibility deal with Lohmann Therapie-Systeme to produce an oral psilocybin thin film strip "While our Phase 3 clinical study for COVID-19 is ongoing in the USA, we are laying the groundwork by partnering with Supriya to execute on our global manufacturing and commercialization plans and leveraging their regulatory expertise and commercial reach with 78 countries they currently supply pharmaceutical products to,” said Michael Frank, CEO of Revive Therapeutics, in a statement. "We are focused on completing our current Phase 3 study in the USA and also obtaining EUA. These results will support drug approval registrations globally, including India, Europe, and Canada." Dr Satish Wagh, of Supriya Lifescience, added: "Through this collaboration, we aim to join our forces with Revive to accelerate access to Bucillamine in India at a time when it is most needed. "This is a step towards making more treatment options available to patients in India in dealing with the pandemic. With this partnership, Supriya aims to enter into a niche area of chemistry and products, thereby bolstering its CMO and research capabilities.” Mumbai-based Supriya is an EU GMP and US FDA-approved manufacturer and supplier of active pharmaceuticals ingredients and pharmaceutical products and exports to 78 countries (in fiscal 2021). Revive Therapeutics is focused on the research and development of therapeutics for infectious diseases and rare disorders. In the statement, it also noted that it is not "making any express or implied claims" that its product can eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time. Contact the author at giles@proactiveinvestors.com